肺腺癌18F-FDG PET/CT代谢参数与肿瘤微环境免疫生物标志物表达的相关性
本研究纳入134例肺腺癌患者,探讨FDG PET/CT代谢参数与肿瘤微环境中FOXP3-TILs、CD8-TILs、CD4-TILs、CD68-TAMs及Gal-1表达的相关性。结果显示代谢参数与FOXP3-TILs和CD68-TAMs正相关,与CD4-TILs和CD8-TILs负相关;肿瘤分期、Gal-1表达和CD8-TILs为总生存的独立危险因素。结论提示FDG PET可能有助于全面评估肿瘤微环境并预测免疫治疗反应。
要点
- FDG PET代谢参数越高,FOXP3-TILs和CD68-TAMs浸润越多,CD8-TILs越少。
- SUVmax、MTV、TLG与CD8-TILs呈负相关,提示代谢活跃肿瘤免疫抑制更强。
- 肿瘤分期、Gal-1表达和CD8-TILs是总生存的独立危险因素。
关键影像表现/征象
- SUVmax、MTV、TLG与FOXP3-TILs覆盖的IRA%呈正相关(rho=0.437、0.400、0.414,p<0.0001)。
- SUVmax、MTV、TLG与CD68-TAMs覆盖的IRA%呈正相关(rho=0.356、0.355、0.354,p<0.0001)。
- SUVmax、MTV、TLG与CD8-TILs覆盖的IRA%呈负相关(rho=-0.305、-0.316、-0.322,p<0.0001)。
- SUVmax、MTV、TLG与CD4-TILs覆盖的IRA%呈负相关(rho=-0.164、-0.190、-0.191;p=0.059、0.028、0.027)。
- Gal-1表达与FOXP3-TILs和CD68-TAMs覆盖的IRA%正相关(rho=0.379、0.370,p<0.0001),与CD8-TILs负相关(rho=-0.347,p<0.0001)。
临床应用与阅片要点
- 阅片时可关注SUVmax、MTV、TLG较高者,提示FOXP3-TILs和CD68-TAMs浸润较多、CD8-TILs较少。
- 代谢参数结合Gal-1表达和CD8-TILs有助于评估预后和免疫治疗潜在反应。
局限性
- 单中心回顾性研究,样本量134例,结论需多中心验证。
- 免疫组化分析为半定量方法,可能存在观察者间差异。
- 未报告代谢参数诊断免疫标志物表达的阈值或敏感度/特异度。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
AIM: To explore the association between metabolic parameters evaluated by integrated 2-[18F]-fluoro-2-deoxy-d-glucose (FDG) positron-emission tomography (PET)/computed tomography (CT) and the expression of immune biomarkers in the tumour microenvironment in lung adenocarcinoma.
MATERIALS AND METHODS: This study included 134 patients. Metabolic parameters were obtained by PET/CT. Immunohistochemistry analysis was used for FOXP3-TILs (transcription factor forkhead box protein 3 tumour-infiltrating lymphocytes), CD8-TILs, CD4-TILs, CD68-TAMs (tumour-associated macrophages) and galectin-1 (Gal-1) tumour expression.
RESULTS: There were significant positive associations between FDG PET metabolic parameters and the median percentage of immune reactive areas (IRA%) covered by FOXP3-TILs and CD68-TAMs. Negative associations with the median IRA% covered by CD4-TILs and CD8-TILs were observed: maximal standardised uptake value (SUVmax), metabolic tumour volume (MTV), total lesion glycolysis (TLG), and IRA% for FOXP3-TILs (rho = 0.437, 0.400, 0.414; p<0.0001 for all parameters); SUVmax, MTV, TLG, and IRA% for CD68-TAMs (rho = 0.356, 0.355, 0.354; p<0.0001 for all parameters); SUVmax, MTV, TLG, and IRA% for CD4-TILs (rho = -0.164, -0.190, -0.191; p=0.059, 0.028, 0.027, respectively); SUVmax, MTV, TLG, and IRA% for CD8-TILs (rho = -0.305, -0.316, -0.322; p<0.0001 for all parameters). There were significant positive associations between tumour Gal-1 expression and the median IRA% covered by FOXP3-TILs and CD68-TAMs (rho = 0.379; p<0.0001; rho = 0.370; p<0.0001, respectively), and a significant negative association with the median IRA% covered by CD8-TILs (rho = -0.347; p<0.0001) was observed. Tumour stage (p=0.008), Gal-1 expression (p=0.008), and median IRA% covered by CD8-TILs (p=0.054) were independent risk factors for overall survival.
CONCLUSION: FDG PET may facilitate a comprehensive evaluation of the tumour microenvironment and predict response to immunotherapy.
引用
- Li, Xuan, Zheng, et al. Correlation of 18F-FDG PET/CT metabolic parameters with the expression of immune biomarkers in the tumour microenvironment in lung adenocarcinoma. Clin Radiol. 2023. PMID: 36934052. doi:10.1016/j.crad.2023.02.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。